Fig. 3.

ppp-RNA treatment depends on intact IFN alpha signaling. a As depicted in the schematic C57BL/6 WT, Mavs^−/− and Ifnar1^−/− mice were treated with 50 μg of ppp-RNA on days 3, 7, 10, and 14 after inoculation with C1498-GFP AML cells. Blood was drawn after the first (day 3) and fourth (day 14) treatment, and levels of murine CXCL10 were measured via ELISA. Each symbol represents a single mouse and error bars indicate SD. Statistical differences between genotypes at one time point were determined by one-way ANOVA with Tukey’s post-hoc test. b Ifnar1^−/− mice (n = 4 per group) were inoculated with C1498-GFP AML cells and treated according to the scheme depicted in a. Survival data were plotted in a Kaplan–Meier survival curve. p = 0.073 for ppp-RNA versus untreated mice. c C1498-GFP AML-bearing C57BL/6 wild type mice (n = 10) were randomized into two groups, of which one received 5 × 10⁴ IU murine IFN alpha (mIFNα) i.p. on days 3, 7, 10, and 14 as depicted in the schematic in c. Survival data were plotted in a Kaplan–Meier survival curve. p = 0.352 for mIFNα treated versus untreated mice. d C57BL/6 Mavs^−/− (n = 9 per group) were treated with 50 μg of ppp-RNA on days 3, 7, 10, and 14 or left untreated according to the scheme depicted in a. Survival data were plotted in a Kaplan–Meier survival curve. The data shown are derived from one (b, c) or two independent (d) experiments